CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.
Profitability
This table compares CRISPR Therapeutics and Caribou Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
| Caribou Biosciences | -1,030.42% | -89.11% | -62.47% |
Earnings & Valuation
This table compares CRISPR Therapeutics and Caribou Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $3.51 million | 1,391.12 | -$581.60 million | ($4.76) | -10.61 |
| Caribou Biosciences | $10.04 million | 4.78 | -$148.12 million | ($1.08) | -0.41 |
Caribou Biosciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
CRISPR Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for CRISPR Therapeutics and Caribou Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 7 | 9 | 2 | 2.63 |
| Caribou Biosciences | 1 | 4 | 1 | 1 | 2.29 |
CRISPR Therapeutics presently has a consensus target price of $65.75, indicating a potential upside of 30.20%. Caribou Biosciences has a consensus target price of $5.00, indicating a potential upside of 1,018.57%. Given Caribou Biosciences’ higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than CRISPR Therapeutics.
Summary
Caribou Biosciences beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
